Abstract: Lung cancer is one of the most common cancers in the world. With the popularization of low-dose CT lung cancer screening, the detection rate of stage ⅠA non-small cell lung cancer (NSCLC) is increasing. ¹⁸F-fluorodeoxyglucose (FDG) PET/CT as an imaging method to reflect the metabolic state of tumor cells at the molecular level, has become an important tool for the diagnosis, staging and prognosis of NSCLC. The clinical application of PET/CT in stage ⅠA NSCLC is increasing year by year. This paper reviews the research related to the application of ¹⁸F-FDG PET/CT in stage ⅠA NSCLC patients in recent years, and the value of these researches in clinical decision-making and prognosis.